"Advancing P2Y$_{12}$ Receptor–Targeted Antiplatelet Therapy in Acute Myocardial Infarction: A Comparative Review of Clopidogrel and Selatogrel"

Mr. Tejas Pandurang Bhagwat*, Dr. Priyanka Kundlik Sabale, Dr. Jaydeep Babasaheb Pawar ,
Prof. Amarsinh Suresh Devdhe, Ms. Dhanashri Sadashiv Punde.

Department of Pharmacology, Shantiniketan College of Pharmacy Dhotre Bk. Tal-Parner,
Dist-Ahilyanagar, Maharashtra, India 414304

Corresponding Authors Details: Mr. Tejas Pandurang Bhagwat, Second Year M. Pharmacy, Department of Pharmacology, Shantiniketan College of Pharmacy Dhotre Bk. Tal-Parner, Dist-Ahilyanagar, Maharashtra, India 414304

Email ID- bhagwattejas1@gmail.com

1. Abstract

Acute myocardial infarction (AMI) continues to be a major contributor to global cardiovascular morbidity and mortality. Rapid platelet activation following atherosclerotic plaque rupture plays a pivotal role in coronary thrombus formation, making early and effective antiplatelet therapy a cornerstone of AMI management.

Clopidogrel, an oral P2Y$_{12}$ receptor inhibitor, has been widely used in acute coronary syndromes; however, its clinical effectiveness is limited by delayed onset of action, irreversible platelet inhibition, and interindividual variability related to genetic polymorphisms of hepatic enzymes.

Selatogrel is a novel, direct-acting, reversible P2Y$_{12}$ receptor antagonist administered via the subcutaneous route. It provides rapid and predictable platelet inhibition without the need for metabolic activation, offering a potential advantage in the early and pre-hospital phase of AMI care.

This review compares the pharmacological, mechanistic, and clinical aspects of clopidogrel and selatogrel, highlighting the potential advantages of selatogrel in acute myocardial infarction.

If Selatogrel ongoing trials are successful could revolutionize pre-hospital AMI care by enabling very early platelet inhibition at symptom onset, even before reaching the hospital. Its rapid and reliable action overcomes the delays seen with oral drugs, while self-administration helps bridge the treatment gap, potentially reducing ischemic events and mortality.

Keywords- Acute Myocardial Infarction, Antiplatelet Therapy, P2Y$_{12}$ Receptor, Clopidogrel, Selatogrel, Pharmacogenomics, CYP2C19, Reversible Inhibition, Pre-hospital Management

2. Introduction

Acute myocardial infarction (AMI) is a critical cardiovascular emergency caused by the sudden occlusion of coronary blood flow, leading to myocardial ischemia and irreversible necrosis. It remains one of the leading causes of morbidity and mortality worldwide. Early platelet activation and aggregation play a central role in thrombus formation, and prompt platelet inhibition is crucial in limiting infarct size and improving clinical outcomes.



(Fig no 1. Acute Myocardial Infarction)

In India, AMI represents a major epidemiological burden, as cardiovascular diseases contribute to approximately 25–30% of all deaths. Notably, AMI occurs nearly 10 years earlier in the Indian population compared to Western countries, resulting in high premature mortality and long-term disability. Delays in symptom recognition, limited pre-hospital care, and late initiation of effective antiplatelet therapy further worsen outcomes, highlighting the need for earlier and more reliable treatment strategies.

Clopidogrel, widely used as part of dual antiplatelet therapy, has long been a cornerstone in AMI management. However, its clinical effectiveness is limited by a delayed onset of action and inter-individual variability due to CYP2C19 genetic polymorphisms. These limitations are particularly relevant in populations with a high prevalence of such polymorphisms, including India.

Selatogrel, a new-generation subcutaneous $P2Y_{12}$ receptor antagonist, offers a novel approach to early AMI management. Unlike clopidogrel, selatogrel is a direct-acting and reversible inhibitor that does not require hepatic metabolic activation, providing rapid and predictable platelet inhibition. Its suitability for use during the pre-hospital phase positions selatogrel as a promising agent to address existing gaps in AMI care and potentially reduce the overall disease burden in the Indian population.

3. Evolution of $P2Y_{12}$ Receptor–Targeted Therapy

The introduction of clopidogrel in the late 1990s marked a significant advance in antiplatelet therapy, demonstrating superior outcomes compared with aspirin monotherapy in acute coronary syndromes.

However, clinical experience highlighted important limitations, including delayed onset of action and reduced efficacy in certain patient populations.

Subsequent development of more potent oral $P2Y_{12}$ inhibitors such as prasugrel and ticagrelor addressed some of these issues but introduced concerns related to bleeding risk.

Selatogrel represents a further evolution in antiplatelet therapy, specifically engineered to provide rapid, predictable platelet inhibition suitable for use in the pre-hospital setting.

4. Integration into Emergency Medical Systems

- Selatogrel could be incorporated into **ambulance protocols**, enabling paramedics to administer therapy enroute to hospital.
- This innovation aligns with modern **prehospital care models**, where early intervention significantly improves outcomes.

5. Global Health Implications

- **Clopidogrel**: Affordable and widely available, making it indispensable in low-resource settings.
- **Selatogrel**: While costlier, its rapid action could reduce long-term healthcare costs by lowering mortality and complications.
- Adoption strategies may differ between high-income and low-income countries, highlighting the need for **cost-effectiveness studies**.



Fig no 2- Clopidogrel vs Selatogrel

6. <u>Pharmacological Profile Characteristics</u>

A. Clopidogrel:

A thienopyridine prodrug that **irreversibly** inhibits the **P2Y12** receptor after hepatic activation via CYP2C19. It has a delayed onset of **2–6 hours** and long-lasting effects due to irreversible platelet binding.

B. Selatogrel:

Selatogrel is a potent, direct, and reversible $P2Y_{12}$ receptor antagonist administered via the subcutaneous route. It produces rapid platelet inhibition within approximately 15 minutes, making it suitable for early intervention in acute coronary events.

Unlike thienopyridines, it does not require hepatic metabolic activation, resulting in predictable pharmacokinetics and consistent antiplatelet effects with minimal interindividual variability.

In addition to clopidogrel there are many of oral antiplatelets available such as,

C. Prasugrel:

Prasugrel is a thienopyridine prodrug that irreversibly inhibits the $P2Y_{12}$ receptor following hepatic activation. Compared to clopidogrel, it has more efficient and consistent metabolic activation, resulting in a faster onset of action (≈30–60 minutes) and more potent platelet inhibition, with less influence from CYP2C19 genetic polymorphisms.

D. Ticagrelor:

Ticagrelor is a direct-acting, reversible $P2Y_{12}$ receptor antagonist that does not require metabolic activation. It has a rapid onset of action (≈30 minutes), provides predictable platelet inhibition, and has a shorter duration of effect compared to irreversible $P2Y_{12}$ inhibitors due to reversible receptor binding.

Compared to prasugrel and ticagrelor, selatogrel offers the unique advantage of subcutaneous administration with ultra-rapid platelet inhibition, making it particularly suitable for early pre-hospital use where oral absorption may be delayed or unreliable.



Fig no 3- Comparison of Antiplatelet Drugs in Acute Coronary Events

7. Mechanism of Action

Both clopidogrel and selatogrel inhibit platelet aggregation by blocking the $P2Y_{12}$ receptor, an important ADP-dependent receptor involved in platelet activation and thrombus formation. Under normal conditions, binding of adenosine diphosphate (ADP) to the $P2Y_{12}$ receptor activates intracellular signaling pathways that enhance platelet activation, aggregation, and stabilization of the platelet plug.

Clopidogrel is an oral thienopyridine antiplatelet drug that acts as a prodrug and requires hepatic metabolism by cytochrome P450 enzymes to form its active metabolite. This active metabolite binds irreversibly to the $P2Y_{12}$ receptor, causing permanent inhibition of the receptor for the lifespan of the platelet. As a result, ADP-mediated platelet activation and aggregation are inhibited for a prolonged period, and recovery of platelet function occurs only with the formation of new platelets.

Selatogrel, on the other hand, is a direct-acting $P2Y_{12}$ receptor antagonist administered by the subcutaneous route and does not require metabolic activation. It binds directly and reversibly to the $P2Y_{12}$ receptor, blocking ADP-induced platelet activation and aggregation. Due to its reversible binding, platelet function is restored as the drug is cleared from the body, resulting in a rapid onset and shorter duration of antiplatelet effect.



Fig no 4- MOA of Platelet P2Y12 Receptor

8. Comparative Pharmacokinetics

Table no 1- Comparison of Clopidogrel vs Selatogrel

Parameter	Clopidogrel	Selatogrel
Onset of Action	2–6 hours	5–15 minutes
Duration	7–10 days	≈8 hours
Route	Oral	Subcutaneous
Metabolism	CYP2C19-dependent	None
Reversibility	Irreversible	Reversible

9. Advantages of Selatogrel Over Clopidogrel in Acute Myocardial Infarction (AMI)

Selatogrel offers several potential advantages over clopidogrel in the acute phase of myocardial infarction. Its rapid onset of action enables early platelet inhibition during the critical initial period of ischemia. Subcutaneous administration allows use in pre-hospital settings, including possible self-administration. In addition, its independence from CYP2C19 metabolism ensures consistent efficacy across genetically diverse populations. Reversible receptor binding may also improve safety in patients requiring urgent surgical interventions.



Selatogrel achieves swift platelet inhibition, which is critical during the early stages of myocardial ischemia when timely antiplatelet activity can significantly impact outcomes.



Its subcutaneous delivery allows for potential self-administration, enabling pre-hospital treatment and reducing delays in therapeutic onset.

Unlike clopidogrel, Selatogrel's efficacy is not compromised by CYP2C19 genetic polymorphisms, ensuring consistent therapeutic effects across diverse genetic profiles.



Selatogrel's reversible receptor interaction offers a safety advantage for patients who may require urgent surgical procedures, allowing for quicker restoration of platelet function.

It demonstrates a more uniform pharmacodynamic response, minimizing variability and enhancing reliability across patient populations.

Selatogrel serves effectively as a bridging agent before transitioning to oral $P2Y_{12}$ inhibitors post-hospitalization, maintaining platelet inhibition during critical care transitions.



Its minimal reliance on hepatic metabolism lowers the risk of drug-drug interactions, especially in polypharmacy settings common among AMI patients.



By enabling earlier and more reliable platelet inhibition, Selatogrel may contribute to reduced mortality and improved clinical outcomes in AMI management.

10. Pharmacogenomic Considerations

The antiplatelet response to **clopidogrel** is significantly influenced by genetic polymorphisms of the **CYP2C19 enzyme**, which is required for its metabolic activation. Individuals carrying **loss-of-function alleles** produce lower levels of the active metabolite, resulting in reduced platelet inhibition and an increased risk of ischemic events such as stent thrombosis and recurrent myocardial infarction. These limitations are particularly important in populations with a **high prevalence of CYP2C19 polymorphisms**, including Asian populations.

In contrast, **selatogrel** does not require hepatic metabolic activation and therefore **bypasses CYP2C19-related genetic variability**. This leads to more **predictable and consistent antiplatelet efficacy** across different patient populations. The pharmacogenomic advantage of selatogrel is especially relevant in regions such as **Asia**, where CYP2C19 loss-of-function alleles are more common.

11. Comparisons with Other P2Y12 Inhibitors



Clopidogrel is often compared with **ticagrelor and prasugrel**, which show superior efficacy but higher bleeding risk.

Selatogrel's **reversible binding** may strike a balance between efficacy and safety, potentially reducing bleeding complications compared to irreversible agents.

12. Clinical Trial Updates

SOS-AMI Trial (NCT04957719): Ongoing large-scale study evaluating **self-administered Selatogrel** in patients with suspected AMI. Focuses on mortality reduction and feasibility of pre-hospital use.
Early-phase studies confirm **rapid platelet inhibition within 15 minutes**, sustained for ~8 hours, making it ideal for bridging until oral therapy is initiated.
Trials also explore **patient self-injection kits**, which could revolutionize emergency cardiovascular care.

13. Special Clinical Scenarios-

Cardiogenic shock: Early and potent platelet inhibition improves outcomes in AMI complicated by shock. Selatogrel's rapid onset may be particularly beneficial in these high-risk patients.
Perioperative settings: Clopidogrel's irreversible binding complicates urgent surgery due to bleeding risk. Selatogrel's reversible inhibition allows **faster recovery of platelet function**, improving surgical safety.

14. Safety and Bleeding Risk

Clopidogrel: Associated with **variable bleeding risk**, especially in poor metabolizers or those on interacting drugs (PPIs, SSRIs).

Selatogrel: Early data suggest **lower bleeding risk** due to reversibility, but long-term comparative safety data are still pending.

15. Operational and Practical Advantages



Pre-hospital administration: Selatogrel can be given by paramedics or even self-administered, reducing **time-to-treatment** in AMI — a critical determinant of survival.

Bridging therapy: Provides immediate platelet inhibition until oral agents (clopidogrel, ticagrelor, prasugrel) can be started in hospital.

Drug interactions: Clopidogrel interacts with CYP2C19 inhibitors (omeprazole, fluoxetine), while Selatogrel avoids these issues.

Future Perspectives

Integration into EMS protocols: Selatogrel could be included in emergency kits for high-risk patients.

Cost-effectiveness: Needs evaluation against widely available generics like clopidogrel.

Combination strategies: Potential use with other agents (aspirin, anticoagulants) for tailored therapy.

Precision medicine: Selatogrel aligns with the trend toward **genotype-independent therapies**, ensuring equitable outcomes across diverse populations.

16. Future Research Directions

Combination therapy: Exploring Selatogrel with aspirin or anticoagulants for synergistic effects.

Precision medicine: Selatogrel's genotype-independent action supports personalized treatment strategies.

Long-term outcomes: Ongoing Phase III trials will determine whether early intervention translates into sustained survival benefits.

Clinical Trials and Evidence

Clinical studies, including those published in the Journal of the American College of Cardiology (JACC, 2020) and European Heart Journal (2023), demonstrate that selatogrel achieves rapid platelet inhibition within 15 minutes and maintains efficacy for several hours. Phase II and III trials (e.g., ACT-246475, NCT04765457) confirm its safety, tolerability, and potential for pre-hospital use in suspected AMI.

17. Limitations and Future Scope

Despite its encouraging clinical potential, selatogrel has certain limitations that warrant consideration. At present, long-term safety data are limited, as most available evidence is derived from early-phase clinical trials and ongoing studies, and its safety profile with repeated or widespread use is yet to be fully established. Furthermore, issues related to cost and accessibility—particularly in low- and middle-income countries such as India—may affect its practical implementation in routine care. Consequently, large-scale outcome trials and health-economic analyses are essential to better define the long-term safety, affordability, and real-world feasibility of selatogrel.

Projected retail price for selatogrel 16 mg at launch in India may range from ₹4,000 to ₹8,000 per dose, reflecting its novel formulation and initial branded positioning. High early cost may limit accessibility in low-resource settings, underscoring the need for economic evaluations and policy planning

18. Conclusion

Clopidogrel remains a standard oral antiplatelet for secondary prevention but has limitations in acute management due to its delayed onset and variability. Selatogrel, with its rapid, reversible, and consistent inhibition, represents a major advancement for early intervention in AMI. If validated in ongoing Phase III trials, it could redefine the pre-hospital management of myocardial infarction.

19. Short Summary

Acute myocardial infarction (AMI) is a life-threatening condition in which early platelet activation leads to coronary thrombosis. Timely antiplatelet therapy is essential to improve outcomes. Clopidogrel, a commonly used oral $P2Y_{12}$ inhibitor, is effective but has important limitations, including delayed onset of action and variable response due to genetic factors.

Selatogrel is a new subcutaneous, direct, and reversible $P2Y_{12}$ receptor inhibitor that provides rapid and predictable platelet inhibition without the need for metabolic activation. Its fast action and suitability for pre-hospital use make it a promising option for early AMI management, including possible self-administration.

If ongoing clinical trials confirm its benefits, selatogrel could significantly improve early treatment of AMI by bridging the critical time between symptom onset and hospital-based oral therapy, potentially reducing complications and mortality.



Fig no 5. Bridge for Acute Myocardial Treatment

20. References

1. Storey RF, Gurbel PA, ten Berg J, et al. Pharmacodynamic effects of selatogrel, a novel reversible $P2Y_{12}$ receptor inhibitor. J Am Coll Cardiol. 2020;75(7):721–730.

2. **Tripathi KD.**
***Essentials of Medical Pharmacology*.** 9th ed. New Delhi: Jaypee Brothers Medical Publishers; 2024.Page: 203–205 (Drug therapy of myocardial infarction); 288–292 (Antiplatelet drugs).

3. Hsin C, Dingemanse J, Henrich A, et al. Mind the gap: model-based switching from selatogrel to maintenance therapy with oral $P2Y_{12}$ receptor antagonists. Biomolecules. 2023;13(9):1365.

4. Brunton LL, Hilal-Dandan R, Knollmann BC, editors. ***Goodman & Gilman's The Pharmacological Basis of Therapeutics***. 14th ed. New York: McGraw-Hill Education; 2023. page. 747–760, 803–820.

5. Angiolillo DJ, Rollini F. ST-elevation myocardial infarction antithrombotic therapy: the evolving role of $P2Y_{12}$ inhibitors. Front Cardiovasc Med. 2024;11:1310642.

6. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. The pharmacogenomics of clopidogrel: CYP2C19 polymorphisms and clinical outcomes. Circulation. 2009;120(25):2271–2277.

7. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057.

8. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015.

9. Angiolillo DJ, Bhatt DL. Oral $P2Y_{12}$ inhibitors and drug–drug interactions. Eur Cardiol Rev. 2021;16:e21.

10. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation (CURE trial). N Engl J Med. 2001;345(7):494–502.

11. ClinicalTrials.gov. Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (SOS-AMI). Identifier: NCT04957719.

12. European Heart Journal. Clinical development of selatogrel as a fast-acting $P2Y_{12}$ inhibitor. Eur Heart J. 2023;44:3132–3143

13. **Rang HP, Dale MM**, Ritter JM, Flower RJ, Henderson G. *Rang & Dale's Pharmacology*. 9th ed. London: Elsevier; 2020. p. 291–305, 319–332.

14. Gawaz M, editor. Antiplatelet Agents. Handbook of Experimental Pharmacology. Vol. 210. Berlin, Heidelberg: Springer; 2012. page. 147–170.

15. Price MJ, Angiolillo DJ, editors. Antiplatelet and Anticoagulation Therapy in Percutaneous Coronary Intervention. Philadelphia: Elsevier; 2018.

page. 85–102 (Clopidogrel: pharmacology and clinical limitations);

page. 215–228 (Emerging therapies: selatogrel and novel $P2Y_{12}$ inhibitors).

16. Patrono C, Morais J, editors. Antiplatelet Therapy in Cardiovascular Disease. Cham: Springer; 2017. page. 55–72 (Dual antiplatelet therapy in acute coronary syndromes); page. 143–158 (Pharmacogenomics and variability in clopidogrel response).